MALIGNANT FIBROUS HISTIOCYTOMA. THE RESULTS OF COMBINED TREATMENT OF RESECTABLE FORMS
Background. We studied the patients' outcome with respectable forms of malignant fibrous histiocytoma according to the type of chemotherapy. Methods. We performed a retrospective analysis of 53 patients with malignant fibrous histiocytoma treated in the N.N. Blokhins Russian Cancer Research Center from 2000 to 2010. All patients underwent radical surgery. Neoadjuvant chemotherapy was administered in 7 (13%) patients, adjuvant chemotherapy - in 5 (9%), neo and adjuvant chemotherapy - in 13 (24%) patients, chemotherapy was not done in 28 (54%) patients. Result. Progression of the disease was revealed in 6/7 (86%), 7/18 (39%), 17/28 (60%) respectively. Conclusion. Patients with MFH should be prescribed adjuvant chemotherapy for reducing the risk of relapse.